Clearbridge Investments LLC Sells 224,953 Shares of Elanco Animal Health Incorporated $ELAN

Clearbridge Investments LLC trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,672,645 shares of the company’s stock after selling 224,953 shares during the quarter. Clearbridge Investments LLC’s holdings in Elanco Animal Health were worth $128,372,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Elanco Animal Health during the first quarter worth $2,065,000. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after acquiring an additional 295,651 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Jeffrey N. Simmons purchased 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Trading Down 0.1%

Shares of ELAN stock opened at $23.61 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. Elanco Animal Health Incorporated has a 52-week low of $13.15 and a 52-week high of $27.72. The company has a market capitalization of $11.79 billion, a PE ratio of -47.22, a price-to-earnings-growth ratio of 1.55 and a beta of 1.69. The business’s fifty day moving average is $22.88 and its 200 day moving average is $23.40.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter last year, the business posted $0.37 earnings per share. The firm’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of several recent research reports. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Morgan Stanley increased their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.